AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 92 min read$JNJ

Johnson & Johnson Announces New Two-Year Results from Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE in Adults and Adolescents with Moderate-To-Severe Plaque Psoriasis

Johnson & Johnson presented two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE® in moderate-to-severe plaque psoriasis. Data showed high skin clearance rates and sustained symptom improvement with no new safety signals. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The study included 684 participants, with 66 adolescents. ICOTYDE is approved in the U.S., Europe, Japan, and China for psoriasis treatment.

Original reporting
marketscreener.com
Published Oct 9, 2026, 3:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 3:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The trial data could expand market share and support future label extensions.

02

Market read

First report of pivotal trial results; may move JNJ stock and influence dermatology sector.

03

What to watch

Potential competition from other IL‑23 inhibitors and the need for regulatory filings.

Relevance 7/10Novelty 8/10Timing: today

Background

Johnson & Johnson's ICOTYDE is an oral peptide IL‑23 receptor blocker approved for moderate‑to‑severe plaque psoriasis.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson released new two-year Phase 3 ICONIC-LEAD data for ICOTYDE showing 72% PASI‑90 and 44% PASI‑100 responses at Week 112.

Expected impact

likely upward pressure as investors price in the strong efficacy data

Evidence & confidence

First disclosure of pivotal trial outcomes with high response rates; no prior public release.

Market effects

Sector

Strengthens the dermatology/psoriasis treatment segment and may pressure competitors.

Regional

Positive for US and European markets where JNJ trades.

Global

Highlights US biotech leadership in IL‑23 targeted therapies.

Counterpoint

What could challenge this read

If pricing or reimbursement concerns arise, the data may not translate into sales.

Key entities

  • Company
    Johnson & Johnson

    US‑listed pharmaceutical and consumer health conglomerate.

Read at source← All news

StoryJohnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis

Also covered by

3 outlets

Related articles

OCT 9
$BSXMed

Boston sues J&J subsidiary over alleged patent infringement for cardiology device

Boston Scientific sued Johnson & Johnson subsidiary Atraverse Medical, alleging patent infringement by its Hotwire device. Boston claims Atraverse knew its actions infringed Patent '955 and seeks damages and an injunction. J&J acquired Atraverse in 2026. The electrophysiology ablation catheter market is growing at 11.1% CAGR, with J&J's Biosense Webster leading at 43.1% market share in 2025.

finance.yahoo.com2 min
OCT 9
$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

mugglehead.com2 min
OCT 9
$JNJMed

Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

rttnews.com2 min
OCT 9
$JNJMed

Johnson & Johnson Reports Positive Two-Year Data on ICOTYDE for

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.

gurufocus.com3 min